For in vitro diagnostic use. The RIDA®GENE Flu test, performed on the Roche LightCycler® 480II, is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of influenza virus RNA (influenza A, influenza B, and H1N1v) in untreated human nasal/throat swabs from persons with signs and symptoms of acute respiratory infection.
The RIDA®GENE Flu test is intended to support the differential diagnosis of influenza virus infections in patients with symptoms of respiratory infection in connection with other clinical and laboratory findings.
Negative results do not rule out infection with influenza virus and should not be used as the sole basis for diagnosis.
The product is intended for use by professionals working in hospital laboratories, reference laboratories, private laboratories, or public laboratories.
Also called the flu, influenza is one of the most significant infectious respiratory diseases, and it is caused by influenza viruses.
Worldwide three to five million people contract influenza every year, and approximately 290,000 to 650,000 people die from the illness. The annual influenza epidemics can have major impacts on the health care system and the economy.
In the 2018/19 season, estimates put the number of influenza-related doctor’s visits in Germany at about 3.8 million. The number of influenza-related hospitalizations from primary care practices was estimated at 18,000 cases.
The Working Group on Influenza (AGI) of the Robert Koch Institute estimates there are between one and seven million influenza-related doctor’s visits each year. During a severe wave of the flu, like in the 2012/13 and 2017/18 season, there were an estimated 30,000 influenza-related hospitalizations and 20,000 to 25,000 deaths. In contrast, mild seasons (like 2013/14) see only an estimated 3,000 hospitalizations, and influenza-associated excess mortality is not detected.
Influenza viruses are RNA viruses belonging to the family Orthomyxoviridae and are divided into subtypes A, B, and C. Characteristic for influenza viruses is their high variability of the surface antigens hemagglutinin (HA) and neuraminidase (NA) due to mutations (antigenic drift). The influenza types A and B cause the annual flu epidemics, while infections with influenza C viruses cause only mild illness.
Epidemiologically, influenza A viruses are the most important due to their diversity: They were responsible for three pandemics in the 20th century, as well as the majority of flu epidemics. The majority of influenza A infections in humans are caused by the subtypes H1N1 and H3N2. In addition to the antigenic drift resulting from mutation, the mixing of a human and nonhuman influenza A strain can create new influenza A subtypes (antigenic shift), which can trigger a pandemic. The influenza A subtype H1N1 is associated with past and potentially new flu pandemics (e.g., the Spanish flu in 1918/19 and the swine flu in 2009). Today this influenza A subtype is called H1N1v. Influenza viruses are transmitted by droplets and aerosols. The incubation period is one to four days. Clinical symptoms are severe, mainly respiratory tract illnesses accompanied by cough and high fever. A sudden onset of symptoms is characteristic. In serious disease courses, pneumonias and bacterial superinfections can occur, which can be fatal especially to the elderly and children.
|real-time RT-PCR with 100 reactions
|24 months after production
|Analytical Sensitivity : ≥ 50 RNA copies per reaction
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.